

1/23

FIG. 1A






FIG. 1B

A. Secreted FimH_{DSG} fully deglycosylated:



B. Membrane-targeted FimH_{LD}CtDAFgpi:



C. Membrane-targeted FimH_{DSG}CtDAFgpi




FIG. 2




FIG. 3A




FIG. 3B

Study Group	5'UTR/FimH gene/3'UTR_polyA	GMT	% Responder
1	WHO/FimH _{LD} -GPI/WHO_80pA	5,405	85
5	WHO/FimH _{D_{SG}} -GPI/WHO_30L70	12,012	100
2	BMD2/FimH _{LD} -GPI/hHBB_80pA	858	70
3	BMD2/FimH _{D_{SG}} -GPI/hHBB_80pA	8,537	95
4	BMD2/FimH _{D_{SG}} -Sec/hHBB_80pA	2,589	100

FIG. 4A




FIG. 4B

Study Group	5'UTR/FimH gene/3'UTR polyA	GMT	% Responder
5	WHO/FimH _{DSG} -GPI/WHO_30L70	12,012	100
3	BMD2/FimH _{DSG} -GPI/hHBB_80pA	8,537	95
6	105/FimH _{DSG} -GPI/hHBB_80pA	21,322	100
7	70/FimH _{DSG} -GPI/hHBB_80pA	11,832	100
8	91/FimH _{DSG} -GPI/C3PO_80pA	14,317	100
9	BMD3/FimH _{DSG} -GPI/hHBBAES_80pA	7,499	100
10	562/FimH _{DSG} -GPI/hHBB_80pA	18,978	100
11	NaCl (negative control)	50	0

6/23

FIG. 5A




FIG. 5B




FIG. 5C





FIG. 5D



10/23

FIG. 6




FIG. 7A





FIG. 7B



13/23

FIG. 8A




FIG. 8B




FIG. 9A
PD2 (wk 6) Neutralizing Antibody




FIG. 9B

FimH _{DSG} construct	GMT	% Responder
BMD2- GPI	3526	100
BMD2- Secreted	1363	95
BMD2- SerGly GPI	3292	100
BMD562- Secreted	1010	95
BMD562- SerGly GPI	2094	100
BMD576- Secreted	2025	95
BMD576- SerGly GPI	7751	100

FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 11




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D




FIG. 13A




FIG. 13B




FIG. 14




FIG. 15A




FIG. 15B




FIG. 15C

